Summary
Quest Diagnostics Inc. (DGX) filed an 8-K report on May 21, 2026, detailing the results of its 2026 Annual Meeting of Stockholders held on May 20, 2026. The primary focus of this filing is the voting outcomes on key corporate governance matters, including director elections and executive compensation. The company saw overwhelming support for its nominated directors, with all nominees being re-elected with substantial 'For' votes, indicating strong shareholder confidence in the current board leadership. Furthermore, shareholders approved the executive compensation as disclosed in the 2026 Proxy Statement through an advisory resolution, and also ratified the appointment of PricewaterhouseCoopers as the independent registered public accounting firm for the fiscal year 2026. Notably, a stockholder proposal advocating for an independent board chairman was not approved, reflecting a preference for the current board structure. Overall, the results signal a positive shareholder sentiment regarding the company's governance and financial oversight.
Key Highlights
- 1All director nominees were re-elected to the board with substantial majority support.
- 2The advisory resolution to approve executive officer compensation received strong approval from shareholders.
- 3PricewaterhouseCoopers was ratified as the independent registered public accounting firm for 2026.
- 4A significant number of non-votes were recorded across most director elections and other proposals.
- 5A stockholder proposal for an independent board chairman was not approved, indicating shareholder preference against this change.
- 6Voting results for all proposals demonstrate a high level of shareholder engagement and alignment with management's recommendations.